中经记者 晏国文 卢志坤 北京报道 2025年12月10日，由《中国经营报》主办的"大重构·大机遇——2025中国医药大健康产业论坛"在北京 隆重召开。 在会上，安科生物（300009.SZ）执行总裁姚建平以"创新引领企业高质量发展"为主题进行了演讲。姚 建平介绍，经过多年的发展，安科生物已经形成了以生物医药为主轴，以中西药物、精准医疗为两翼， 同时积极布局mRNA技术、ADC、溶瘤病毒、细胞治疗、基因治疗等领域，形成了"一主两翼"协同发展 的战略布局。 "百亿安科，百年安科"是安科生物的战略发展目标。姚建平介绍，"百亿"有三个含义：市值百亿元、营 收百亿元、利润百亿元。 据了解，安科生物是中国最早的生物制药公司之一，是2009年首批在创业板上市的公司之一。 安科生物的第一个创新是机制创新，并且创新始于企业成立之初。姚建平介绍："安科生物成立之初是 一家国有企业，由中国科技大学和安徽省生物研究所各占50%的股权。在20世纪90年代中后期，市场经 济时代逐渐拉开帷幕，国有体制改革在艰难中前行。安科生物分别在1995年、1996年和2000年进行过三 次股份制改制。" 自成立以来，安科生物一直以创新为引领，在产品 ...

中经记者 晏国文 卢志坤 北京报道 （安科生物执行总裁姚建平作主题演讲。） 2025年12月10日，由《中国经营报》主办的"大重构 大机遇"2025中国医药大健康产业论坛在北京隆重 召开。 在会上，安科生物（300009.SZ）执行总裁姚建平以"创新引领企业高质量发展"为主题进行了演讲。姚 建平介绍，经过多年的发展，安科生物已经形成了以生物医药为主轴，以中西药物、精准医疗为两翼， 同时积极布局mRNA技术、ADC、溶瘤病毒、细胞治疗、基因治疗等领域，形成了"一主两翼"协同发展 的战略布局。 "百亿安科，百年安科"是安科生物的战略发展目标。姚建平介绍，"百亿"有三个含义：市值百亿元、营 收百亿元、利润百亿元。 据了解，安科生物是中国最早的生物制药公司之一，是2009年首批在创业板上市的公司之一。 在演讲中，姚建平还提到AI与医药研发的结合。"AI+生物技术、生物医药怎么去结合？其实是完全可 以结合的，比如在药物的大分子设计、药物临床前研究的方案设计、临床研究过程中，包括整个临床方 案的推动……都可以用大数据做一些支撑。一个多肽分子或者一个生物大分子，通过AI来设计，可以 大大缩短它的发现时间，可能会从原来的5年 ...

Core Viewpoint - The article discusses the growing market for growth hormone treatments in children, highlighting the increasing demand from parents who wish to enhance their children's height through medical interventions, despite the associated costs and potential side effects [20][21][23]. Group 1: Height Prediction and Growth Factors - A commonly accepted method for predicting a child's future height is based on the parents' heights, with a formula that includes a genetic baseline and a variable component that can be influenced by environmental factors [3]. - Key hormones affecting height during childhood include sex hormones and growth hormones, with the latter determining the growth rate [4]. Group 2: Market Dynamics and Consumer Behavior - The growth hormone market has evolved significantly over the past decade, with companies investing heavily in marketing and education to promote the use of growth hormones for children [17][19]. - The demand for growth hormone treatments has led to a substantial market, with some companies achieving annual revenues in the billions [19]. Group 3: Treatment Options and Costs - Common forms of growth hormone available in the market include powder, short-acting, and long-acting injections, with differences in administration frequency and pricing [5]. - The financial burden of growth hormone treatments can be significant, with families spending tens of thousands of yuan over the years for their children's height enhancement [15][16]. Group 4: Clinical Practices and Parental Expectations - Many parents are increasingly seeking growth hormone treatments for their children, often bringing them to clinics at younger ages than before, driven by societal pressures and personal aspirations [8][10]. - There is a notable trend of parents willing to invest heavily in treatments, reflecting a broader societal perception that height can influence social and economic outcomes [16][21]. Group 5: Regulatory and Market Challenges - The growth hormone market faces challenges such as regulatory scrutiny and price competition due to collective procurement initiatives, which have led to reduced profit margins for manufacturers [23]. - Despite the declining profitability for some companies, the persistent demand from parents for height enhancement treatments remains strong, indicating a complex market landscape [23].